Definium Therapeutics (DFTX) Non-Current Debt (2023 - 2026)

Definium Therapeutics (DFTX) has reported Non-Current Debt for 4 consecutive years, with $40.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Debt rose 85.03% year-over-year to $40.8 million; the TTM figure through Mar 2026 stood at $40.8 million (up 85.03% YoY), while the FY2025 annual figure was $40.6 million, up 85.68% from the prior year.
• Non-Current Debt steadied at $40.8 million in Q1 2026 per DFTX's latest filing, from $40.6 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $41.2 million in Q2 2025 and bottomed at $14.1 million in Q3 2023.
• Historically, Non-Current Debt has averaged $27.1 million across 4 years, with a median of $24.3 million in 2024.
• Annual changes were most pronounced in 2024 — Non-Current Debt jumped 54.67% — and 2025, when it soared 85.68%.
• Definium Therapeutics' Non-Current Debt stood at $14.1 million in 2023, then surged by 54.67% to $21.9 million in 2024, then jumped by 85.68% to $40.6 million in 2025, then rose by 0.48% to $40.8 million in 2026.
• Business Quant data shows DFTX's Non-Current Debt at $40.8 million in Q1 2026, $40.6 million in Q4 2025, and $40.4 million in Q3 2025.